SinoMab BioScience Past Earnings Performance
Past criteria checks 0/6
SinoMab BioScience's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 15.1% per year.
Key information
-9.2%
Earnings growth rate
-5.3%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 15.1% |
| Return on equity | -82.2% |
| Net Margin | -5,535.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Revenue & Expenses BreakdownBeta
How SinoMab BioScience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -243 | 98 | 135 |
| 30 Sep 23 | 1 | -259 | 98 | 150 |
| 30 Jun 23 | 5 | -274 | 99 | 165 |
| 31 Mar 23 | 5 | -279 | 91 | 173 |
| 31 Dec 22 | 4 | -284 | 83 | 180 |
| 30 Sep 22 | 23 | -301 | 108 | 186 |
| 30 Jun 22 | 34 | -318 | 134 | 191 |
| 31 Mar 22 | 30 | -303 | 134 | 195 |
| 31 Dec 21 | 27 | -288 | 133 | 199 |
| 30 Sep 21 | 20 | -222 | 94 | 172 |
| 30 Jun 21 | 13 | -156 | 55 | 146 |
| 31 Mar 21 | 13 | -139 | 63 | 124 |
| 31 Dec 20 | 13 | -123 | 72 | 103 |
| 30 Sep 20 | 6 | -217 | 86 | 166 |
| 30 Jun 20 | 0 | -311 | 100 | 229 |
| 31 Mar 20 | 0 | -294 | 81 | 222 |
| 31 Dec 19 | 0 | -276 | 62 | 214 |
| 31 Dec 18 | 1 | -84 | 9 | 47 |
Quality Earnings: 3681 is currently unprofitable.
Growing Profit Margin: 3681 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3681 is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare 3681's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3681 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 3681 has a negative Return on Equity (-82.25%), as it is currently unprofitable.